Proven Intelligence in Advanced Therapy CMC

Executive Summary

The development of in vivo Chimeric Antigen Receptor (CAR) T-cell therapies introduces a significant shift in Chemistry, Manufacturing, and Controls (CMC) strategy. Unlike traditional ex vivo approaches, in vivo methods require a dual-focus CMC program that rigorously characterizes both the viral vector delivery system (e.g., Lentivirus or AAV) and the genetic payload encoding the CAR construct. A robust analytical and manufacturing framework is necessary to satisfy the stringent requirements of European regulators, including the Paul-Ehrlich-Institut (PEI), and to ensure product consistency, potency, and a well-defined safety profile for Advanced Therapy Medicinal Product (ATMP) submissions.

Frequently Asked Questions

Q: What are the primary CMC challenges when transitioning from ex vivo to in vivo CAR-T development for an Investigational Medicinal Product Dossier (IMPD)?

The primary challenge is managing two interconnected CMC workstreams. First is the scalable production and characterization of the viral vector, ensuring high titer, purity, and infectivity. Second is the analytical validation of the CAR transgene payload itself, including its expression, function, and potential for immunogenicity. Your IMPD submission to German and EU authorities must demonstrate control over both components as a single therapeutic product.

Q: How does vector choice (e.g., Lentivirus vs. AAV) impact the CMC strategy for in vivo CAR-T therapies targeting German clinical trials?

Vector selection directly influences the entire CMC roadmap. Lentiviral vectors, with their capacity for stable integration, require long-term analytical strategies to assess integration site profiles and genotoxicity. AAV vectors, typically non-integrating, demand rigorous characterization of capsid purity, empty/full particle ratios, and pre-existing patient immunity. The choice dictates the specific suite of potency and safety assays required by the EMA for ATMP classification.

Q: Why is deep analytical characterization of the CAR construct a key factor in minimizing clinical risk?

The CAR construct is a novel protein that can elicit an immune response. A comprehensive analytical package that characterizes protein expression and profiles potential epitopes is a core component of de-risking the asset ahead of clinical evaluation, as patient-specific factors can influence immune reactions to transgene products and potentially reduce efficacy.

The Dual-Component CMC Paradigm for In Vivo CAR-T

In vivo CAR-T programs merge the complexities of viral vector manufacturing with the functional requirements of cell engineering. This creates a dual-component system where the vector acts as the delivery vehicle and the CAR construct is the therapeutic payload. A successful regulatory submission hinges on demonstrating a deep understanding and control over the identity, purity, potency, and safety of both elements.

This integrated approach is fundamental for preparing a comprehensive Investigational Medicinal Product Dossier (IMPD) for submission to European authorities like the PEI and EMA. The dossier must present a cohesive narrative that connects vector manufacturing specifications to the predictable in vivo expression and function of the CAR. Regulators expect to see a clear line of sight from vector process controls to the predicted biological activity and safety profile of the expressed CAR in vivo.

Vector Manufacturing and Payload Integrity

The foundation of an in vivo CAR-T program is a robust and scalable vector production process. Whether utilizing lentiviral platforms for stable integration or AAV vectors for their defined tropism, the manufacturing process must yield a product with consistent quality attributes.

Key analytical considerations include:

• Vector Titer and Purity: Accurate quantification of vector copy number and assessment of process-related impurities.

• Capsid/Envelope Integrity: Ensuring the vector is structurally sound and free of aggregates. For AAV, this includes precise measurement of empty-to-full capsid ratios.

• Transgene Sequence Fidelity: Verifying that the genetic sequence of the CAR construct within the vector is correct and stable.

Our scientific leadership and core operational teams carry a track record that includes a 100% successful IND rate since 2019, built on this type of rigorous analytical groundwork. While Franklin Biolabs was formally launched in 2024, this history of success informs our approach to navigating complex CMC requirements, helping sponsors reach their clinical milestones within an 18-24 month timeline.

Phase-Appropriate Potency Assays for Regulatory Alignment

Potency assays are a focal point for regulatory review. For in vivo CAR-T, these assays must be designed to measure the biological activity of the final product. This often requires a multi-tiered strategy that assesses:
1. The vector’s ability to transduce target T-cells.
2. The expression of the CAR on the surface of transduced cells.
3. The functional activity of the engineered cells, such as cytokine release or target cell lysis.

Developing and validating these complex biological assays in a phase-appropriate, GxP-compliant manner is a core requirement for advancing through clinical trials in Germany and the broader EU. Our facilities, spanning over 100,000 sq ft of specialized laboratory and housing space, are equipped for this advanced analytical work

.

The insights from our work in other programs underscore the importance of anticipating patient-specific biological variables. For instance, understanding how a patient’s unique genetic makeup might influence the immune response to a therapeutic protein is a known part of a proactive CMC strategy (PMID: 28137880). This principle directly applies to characterizing the CAR construct to minimize clinical risk.

This technical and regulatory expertise is centralized within our Vector | CMC | Analytics Services group, which provides the integrated support necessary for these complex next-generation therapeutics.

---

---